Correction: Early Treatment Critical: Bexarotene Reduces Amyloid-Beta Burden In Silico.

[This corrects the article DOI: 10.1371/journal.pone.0153150.].

S1 Text, S1 and S2 Tables are incorrect. Please view the corrected S1 Text, S1 and S2 Tables here.

Note on APP/PS1 mice.

(PDF)

Click here for additional data file.

Solver run times and percent changes in final diseased neuron concentration and Aβ42 load.

Each percent change is given in absolute value when compared to results from a run solved with ode45 for a 90 day simulation of a nine month-old APP/PS1 transgenic mouse with mg ⋅ kg−1 bexarotene treatment.

(PDF)

Click here for additional data file.

Percent change of the concentration of healthy brain cells in a 90 day simulation of nine-month-old APP/PS1 mouse with 100 mg ⋅ kg−1 bexarotene treatment.

Parameters are increased by 10%, and the approximate corresponding percent change of the system is given for 0 mg ⋅ kg−1 and 100 mg ⋅ kg−1 of bexarotene.

(PDF)

Click here for additional data file.